OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age

✍ Scribed by Tweddle, Deborah A. ;Pinkerton, C. Ross ;Lewis, Ian J. ;Ellershaw, Caroline ;Cole, Michael ;Pearson, Andrew DJ

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: English
• Weight: 127 KB
• Volume: 36
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/1096-911x(20010101)36:1<239::aid-mpo1058>3.0.co;2-g

✦ Synopsis

Background. This paper reports the toxicity of OPEC/OJEC chemotherapy in stage 4 neuroblastoma patients over 1 year of age. Procedure. Ninety-five patients with stage 4 neuro- blastoma received alternating courses of OPEC/ OJEC-vincristine 1.5 mg/m 2 (O), cisplatin 80 mg/m 2 (P), etoposide 200 mg/m 2 (E), cyclophosphamide 600 mg/m 2 (C), and carboplatin 500 mg/m 2 (J), every 21 days if there was haematological recovery. Results. Seventy out of ninety-five (74%) patients completed seven or more courses and were evaluable for toxicity.

Of these 70 patients, 33% had more than three episodes of fever and sepsis, 35% required more than five blood or platelet transfusions, 36% had grade 2 or more gastrointestinal toxicity and 9% had neurotoxicity. There was a median reduction in GFR of 32 ml/min/1.73 m 2 (-46 to 134) and there was one toxic death. Conclusions. OPEC/OJEC is a well-tolerated therapy for stage 4 neuroblastoma over 1 year of age.